Try our Advanced Search for more refined results

IN RE ASACOL ANTITRUST LITIGATION

  1. January 25, 2018

    Asacol Antitrust Trial Delayed To Let Allergan Appeal Class

    The First Circuit on Thursday granted an indefinite delay of an antitrust trial slated to start next week, allowing Allergan PLC to appeal the certification of a class of unions and grocers who claim the company and a subsidiary manipulated the market with a monopolistic hard switch of available anti-inflammatory drugs.

  2. January 24, 2018

    Allergan Vies For Insurance Coverage Lists In Asacol Trial

    Allergan and Warner Chilcott on Tuesday asked a Massachusetts federal court for an order stating that lists of prescription drugs covered by insurers are admissible evidence during an antitrust trial brought by a class of organizations that purchased ulcerative colitis drug Asacol.

  3. January 08, 2018

    Allergan Fights To Keep Live Testimony In Asacol Trial

    Attorneys for Allergan PLC and subsidiary Warner Chilcott Ltd. asked a Massachusetts federal judge on Monday to block a group of unions and grocers from replacing witness testimony with recorded depositions in the antitrust class action set to go to trial in two weeks.

  4. December 05, 2017

    Buyer Class Fights Allergan Over Causation In Antitrust Row

    A class of end purchasers accusing Allergan PLC and its subsidiary Warner Chilcott Ltd. of stifling competition for their ulcerative colitis drugs urged a Massachusetts federal court Monday not to certify a causation issue, saying they've adequately argued that the companies' alleged wrongdoing caused them harm.

  5. November 09, 2017

    Allergan Can't Nix Antitrust Row As Buyer Class Is Certified

    Allergan PLC and several related companies lost their bid to exit an antitrust suit by end purchasers of an ulcerative colitis drug as a Massachusetts federal judge on Thursday denied their attempt to kill the claims and granted certification to a class of buyers.

  6. October 06, 2017

    Attys Argue For 1/3 Slice Of $15M Asacol Deal Pie As Fees

    Attorneys for direct purchasers who recently struck a $15 million deal in a suit accusing Allergan PLC and its subsidiary Warner Chilcott Ltd. of stifling competition for their drug Asacol urged a Massachusetts federal judge Thursday to hand them almost $5.46 million in fees and expenses, arguing that they are asking for significantly less than the $8.3 million worth of work they did in the case.

  7. September 19, 2017

    Warner Chilcott Seeks Out Of Asacol Antitrust Suit

    Allergan subsidiary Warner Chilcott has told a Massachusetts federal court that pulling its Asacol ulcerative colitis drug off the market pursuant to a federal safety order can't be considered anti-competitive conduct, urging the court to grant it a quick win in an antitrust lawsuit.

  8. September 15, 2017

    Allergan To Pay $15M To End Asacol Antitrust Claims

    A Massachusetts federal judge Thursday granted preliminary approval to a $15 million settlement that would end claims brought by direct purchasers accusing Allergan PLC and its subsidiary Warner Chilcott Ltd. of stifling competition for their ulcerative colitis drugs.

  9. April 12, 2017

    Shire Blasts Allergan's Discovery Bid In Antitrust Suit

    Allergan shouldn't be able to get competitor Shire's most sensitive data to beat back antitrust allegations over an ulcerative colitis drug, Shire told a federal court in Massachusetts on Tuesday.

  10. February 13, 2017

    Buyers Want Patent Suit Docs In Asacol Antitrust Suit

    Wholesalers accusing Warner Chilcott of trying to thwart competition for its ulcerative colitis medications asked a Massachusetts federal court on Friday to force the drugmaker to hand over documents from two patent suits involving Delzicol, saying the information is key to their antitrust claims.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!